Top

Published in:

01-12-2014 | Original Paper

Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer

Authors: Wei Peng, Wei Gao, Jifeng Feng

Published in: Medical Oncology | Issue 12/2014

Abstract

Pancreatic cancer (PC) is the fourth leading cause of cancer-related mortalities in the USA and the sixth leading cause of mortality in China. Recent studies have shown that lncRNAs play important roles in carcinogenesis. The aim of this study was to explore the role of lncRNA HULC in PC. Quantitative real-time PCR was performed to investigate the expression of HULC in tumor tissues and corresponding normal tissues from 304 patients with PC. The higher expression of HULC was significantly correlated with large tumor size, advanced lymph node metastasis and vascular invasion. Multivariate analyses revealed that HULC expression served as an independent predictor for overall survival (P = 0.032). Further experiments revealed that HULC knockdown significantly repressed cell proliferation of PC in vitro. In conclusion, our results suggest that HULC may serve as a candidate prognostic biomarker through growth regulation in human PC.

Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63(5):318–48. doi:10.3322/caac.21190.PubMedCentralPubMedCrossRef

Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039–49. doi:10.1056/NEJMra1404198.PubMedCrossRef

Crawford SM. The importance of primary care for cancer diagnoses. Lancet Oncol. 2014;15(2):136–7. doi:10.1016/S1470-2045(14)70013-0.PubMedCrossRef

Mattick JS, Makunin IV. Non-coding RNA. Human molecular genetics. 2006;15 Spec No 1:R17-29. doi:10.1093/hmg/ddl046.

Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–9. doi:10.1038/nrg2521.PubMedCrossRef

Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non-coding RNAs: regulators of disease. J Pathol. 2010;220(2):126–39. doi:10.1002/path.2638.PubMedCrossRef

Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10. doi:10.1186/1476-4598-10-38.

Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, Zhang F, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol. 2011;18(5):1243–50. doi:10.1245/s10434-011-1581-y.PubMedCrossRef

Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene. 2013;32(13):1616–25. doi:10.1038/onc.2012.193.PubMedCentralPubMedCrossRef

10.

Nie Y, Liu X, Qu SH, Song EW, Zou H, Gong C. Long non-coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival. Cancer Sci. 2013;104(4):458–64. doi:10.1111/cas.12092.PubMedCrossRef

11.

Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 2012;29(3):1810–6. doi:10.1007/s12032-011-0004-z.PubMedCrossRef

12.

Han YH, Liu YC, Zhang H, Wang TT, Diao RY, Jiang ZM, et al. Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long non-coding RNA MALAT1. FEBS Lett. 2013;587(23):3875–82. doi:10.1016/j.febslet.2013.10.023.PubMedCrossRef

13.

Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han Z, et al. Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex. Br J Cancer. 2014;111(4):736–48. doi:10.1038/bjc.2014.383.PubMedCrossRef

14.

Jiang Y, Li YH, Fang SJ, Jiang BY, Qin CF, Xie PL, et al. The role of MALAT1 correlates with HPV in cervical cancer. Oncol Lett. 2014;7(6):2135–41. doi:10.3892/ol.2014.1996.PubMedCentralPubMed

15.

Ren SC, Liu YW, Xu WD, Sun Y, Lu J, Wang FB, et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol. 2013;190(6):2278–87. doi:10.1016/j.juro.2013.07.001.PubMedCrossRef

16.

Wang JQ, Su LP, Chen XH, Li P, Cai Q, Yu BQ, et al. MALAT1 promotes cell proliferation in gastric cancer by recruiting SF2/ASF. Biomed Pharmacother. 2014;68(5):557–64. doi:10.1016/j.biopha.2014.04.007.PubMedCrossRef

17.

Wu XS, Wang XA, Wu WG, Hu YP, Li ML, Ding Q, et al. MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway. Cancer Biol Ther. 2014;15(6):806–14. doi:10.4161/cbt.28584.PubMedCentralPubMedCrossRef

18.

Kam Y, Rubinstein A, Naik S, Djavsarov I, Halle D, Ariel I, et al. Detection of a long non-coding RNA (CCAT1) in living cells and human adenocarcinoma of colon tissues using FIT-PNA molecular beacons. Cancer Lett. 2014;352(1):90–6. doi:10.1016/j.canlet.2013.02.014.PubMedCrossRef

19.

Crea F, Watahiki A, Quagliata L, Xue H, Pikor L, Parolia A, et al. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget. 2014;5(3):764–74.PubMedCentralPubMed

20.

Wang JY, Liu XF, Wu HC, Ni PH, Gu ZD, Qiao YX, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010;38(16):5366–83. doi:10.1093/nar/gkq285.PubMedCentralPubMedCrossRef

21.

Zhao Y, Guo QH, Chen JJ, Hu J, Wang SW, Sun YM. Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol Rep. 2014;31(1):358–64. doi:10.3892/or.2013.2850.PubMed

22.

Liu Y, Pan SD, Liu L, Zhai XJ, Liu JB, Wen J et al. A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. Plos One. 2012;7(4). doi:10.1371/journal.pone.0035145.

23.

Huang JL, Zheng L, Hu YW, Wang Q. Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma. Carcinogenesis. 2014;35(3):507–14. doi:10.1093/carcin/bgt405.PubMedCrossRef

24.

Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–17. doi:10.1056/NEJMra0901557.PubMedCrossRef

Title: Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer
Authors: Wei Peng
Wei Gao
Jifeng Feng
Publication date: 01-12-2014
Publisher: Springer US
Published in: Medical Oncology / Issue 12/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0346-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2014

An association between the −41657 C/T polymorphism of X-ray repair cross-complementing 2 (XRCC2) gene and ovarian cancer

MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer

NCOA5 low expression correlates with survival in esophageal squamous cell carcinoma

RETRACTED ARTICLE: A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients

Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer

A difficulty in improving population survival outcome of gastric cancer in mainland China: low proportion of early diseases

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials